| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/02/2002 | WO2001090074A3 BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| 05/02/2002 | WO2001087316A3 Composition and method for increasing testosterone levels |
| 05/02/2002 | WO2001085165A3 Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system |
| 05/02/2002 | WO2001082913A3 Use of benzamide derivatives for the treatment of high ocular tension and glaucoma |
| 05/02/2002 | WO2001081298A3 Cyclic carboxylic acids as integrin antagonists |
| 05/02/2002 | WO2001074900A3 Nuclear factor kb inducing factor |
| 05/02/2002 | WO2001074840A3 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregna 21-substituted 19-norpregnadienedione as antiprogestational agents |
| 05/02/2002 | WO2001074401A3 Camptothecin complexes |
| 05/02/2002 | WO2001070756A3 Lipopolysaccharides (lps) extracted from escherichia coli |
| 05/02/2002 | WO2001070733A3 Di-substituted iminoheterocyclic compounds |
| 05/02/2002 | WO2001066772A3 Heparinase iii and uses thereof |
| 05/02/2002 | WO2001064741A3 Methods for selectively modulating survivin apoptosis pathways |
| 05/02/2002 | WO2001064642A3 Benzamides and related inhibitors of factor xa |
| 05/02/2002 | WO2001062289A3 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant |
| 05/02/2002 | WO2001062266A3 Use of dpp-iv inhibitors for the treatment of diabetes |
| 05/02/2002 | WO2001062082A3 Use of phenylethylamine derivatives for the anitmicrobial treatment of surfaces |
| 05/02/2002 | WO2001061009A3 Polypeptides and nucleic acids encoding same |
| 05/02/2002 | WO2001061008A3 Polypeptides and nucleic acids encoding same |
| 05/02/2002 | WO2001057189A3 Fas pathway genes |
| 05/02/2002 | WO2001056544A3 Shell-and-core dosage form approaching zero-order drug release |
| 05/02/2002 | WO2001055210A3 Human cyr61 |
| 05/02/2002 | WO2001054686A3 L-arginine in combination with other compounds for treating cardiovascular diseases |
| 05/02/2002 | WO2001052829A3 Statin-type bone growth stimulators |
| 05/02/2002 | WO2001051635A3 Novel stra6 polypeptides |
| 05/02/2002 | WO2001049280A3 Weight promoting composition, method, and product |
| 05/02/2002 | WO2001048209A3 Genes identified as required for proliferation of e. coli |
| 05/02/2002 | WO2001045688A3 Use od desloratadine for treating allergic and inflammatory conditions in pediatric patients |
| 05/02/2002 | WO2001045667A3 Water-soluble powders for oral solution and use thereof |
| 05/02/2002 | WO2001044264A3 Novel stromelysin inhibitors |
| 05/02/2002 | WO2001042207A3 Novel methods for the treatment and prevention of ileus |
| 05/02/2002 | WO2001040253A3 3-methylene steroid derivative for the treatment of autoimmune diseases |
| 05/02/2002 | WO2001039762A3 Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system |
| 05/02/2002 | WO2001035949A3 Treatment or systemic lupus erythematosus (sle) with dehydroepiandrosterone |
| 05/02/2002 | WO2001034767A3 22 human secreted proteins |
| 05/02/2002 | WO2001032181A3 Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum |
| 05/02/2002 | WO2001029071A3 Genes associated with obesity and methods for using the same |
| 05/02/2002 | WO2001029070A3 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 05/02/2002 | WO2001023375A3 Substituted pyridines and pyridazines with angiogenesis inhibiting activity |
| 05/02/2002 | WO2001022949A3 Use of alprostadil (prostaglandin e1) for producing a medicament for angioneogenesis |
| 05/02/2002 | WO2001009121A3 2-pyrazolin-5-ones_as tyrosine kinase inhibitors |
| 05/02/2002 | WO2001008671A3 Method and composition for prophylaxis and treatment of symptoms associated with cold and influenza-like illnesses |
| 05/02/2002 | WO2001002423A9 2'-guanidinyl-substituted oligonucleotides and gene expression modulation therewith |
| 05/02/2002 | WO2000078972A3 Regulation with binding cassette transporter protein abc1 |
| 05/02/2002 | WO2000075365A9 COMPOUNDS AND METHODS TO ENHANCE rAAV TRANSDUCTION |
| 05/02/2002 | WO2000061124A3 Use off cell membrane penetrating indigoid bisindole derivatives |
| 05/02/2002 | WO2000059491A3 Methods for modulating the human sexual response |
| 05/02/2002 | US20020053093 By use of biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen |
| 05/02/2002 | US20020052693 Pharmacophore models for, methods of screening for, and identification of the cytochrome P-450 inhibitory potency of neurokinin-1 receptor antagonists |
| 05/02/2002 | US20020052530 Such as 3-(N-1-indanylamino)-indan-1-one 3-(N-1-indanylamino) indan-1-one formed by reacting amino-indane compound with bromo-indanone compound in presence of triethyleneamine |
| 05/02/2002 | US20020052527 Novel process for preparing alendronic acid |
| 05/02/2002 | US20020052514 1-(phenylmethyl)sulfonyl-2-hydroxymethyl pyrrolidine for example; use treating neurological disorders including physically damaged nerves and neurodegenerative diseases; treating alopecia and promoting hair growth |
| 05/02/2002 | US20020052513 Oxamide IMPDH inhibitors |
| 05/02/2002 | US20020052512 Diaminopropionic acid derivatives |
| 05/02/2002 | US20020052510 N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres |
| 05/02/2002 | US20020052508 Heterocyclic thioamide derivatives |
| 05/02/2002 | US20020052504 N-((2-cyclopropoxy-5-(1H-tetrazol-1-))phenyl)methyl-2-(4 -phenyl)piperidin-3-amine and derivatives; in particular as neurokinin-1 receptor antagonists; analgesics; migraines; antiinflammatory, anxiolytic, emetic agents; antidepressants |
| 05/02/2002 | US20020052502 Cis-substituted aminocyclopropane derivative |
| 05/02/2002 | US20020052498 (2-substituted oxyphenyl)alkanamide derivative, hair growth promoter and external composition for skin using the same |
| 05/02/2002 | US20020052497 Compounds capable of activating cholinergic receptors |
| 05/02/2002 | US20020052495 Pyramidine or triazine derivatives which specifically inhibit the binding of endothelin to the receptor |
| 05/02/2002 | US20020052483 Intestinal trefoil proteins |
| 05/02/2002 | US20020052477 Fibroblast growth factor homologous factor-1 (fhf-1) and methods of use |
| 05/02/2002 | US20020052443 Non-antigenic branched polymer conjugates |
| 05/02/2002 | US20020052422 Oral drug delivery compositions and methods |
| 05/02/2002 | US20020052420 Inhibiting or preventing a condition associated with undesired secretion of a macrophage inflammatory protein using inhibitors of inosine or inosine derivatives useful for treating inflammatory bowel disease |
| 05/02/2002 | US20020052419 Ophthalmic compositions for soft contact lens, method of enhancing wettability of soft contact lens and method of inhibiting terpenoid adsorption |
| 05/02/2002 | US20020052418 Administering a derivative of a valproic acid amide or a 2-valproenic acid amide to the patient for treating pain and headache disorders |
| 05/02/2002 | US20020052417 Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use |
| 05/02/2002 | US20020052416 Use of prostaglandin EP-3 receptor antagonists as cosmetic agents for attenuating, reducing or stopping the loss of head hair and other hairs |
| 05/02/2002 | US20020052415 Treating chronic uremic patients undergoing periodical dialysis |
| 05/02/2002 | US20020052413 Use of fatty acid derivatives (FADs) and in particular of 13,14-diyhdro-15-keto-prostaglandins in drug manufacturing for treatment of ocular complications such as: vasospastic glaucoma, vasosastic syndrome and other vision defects |
| 05/02/2002 | US20020052410 Administering to the animal suffering from neurological disorders an amide compound having an affinity for FKBP-type immunophilins |
| 05/02/2002 | US20020052409 Compounds and methods for treating mitochondria-associated diseases |
| 05/02/2002 | US20020052407 Modulating expression, production, or formation of amyloid precursor protein by administering a nonsteroidal antiinflammatory agent that is a cyclooxygenase inhibitor |
| 05/02/2002 | US20020052405 Treating obesity, anxiety disorder, post-traumatic stress disorder, premenstrual syndrome, attention deficit disorder, Tourette syndrome, bulimia nervosa or Shy Drager Syndrome by administering a hydroxycycloalkanephenethyl amine |
| 05/02/2002 | US20020052404 Compositions and methods for treating or preventing diseases of body passageways |
| 05/02/2002 | US20020052403 Taxane formulations |
| 05/02/2002 | US20020052402 An antioxidant in quantities sufficient to prevent, inhibit, reverse deterioration of cognitive function; e.g., vitamins E and C, carnitine and alpha-lipoic acid |
| 05/02/2002 | US20020052401 Benzophenones and sulfones as inhibitors of glycine uptake |
| 05/02/2002 | US20020052400 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. |
| 05/02/2002 | US20020052399 In particular as inhibitors of HIV protease. |
| 05/02/2002 | US20020052398 Pharmaceutical composition of 6-amino EM-12 |
| 05/02/2002 | US20020052397 Treatment of diseases characterized by excess Th2 cytokines and/ or an excess IgE production. |
| 05/02/2002 | US20020052394 Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release |
| 05/02/2002 | US20020052393 Benzanilides as potassium channel openers |
| 05/02/2002 | US20020052392 Have utility as, inter alia, hypoglycemic, and anti-obesity agents. |
| 05/02/2002 | US20020052391 Tetrahydroquinoline derivatives as glycine antagonists |
| 05/02/2002 | US20020052390 Treating non-invasive fungus-induced otitis media by mucoadministering an antifungal agent. |
| 05/02/2002 | US20020052388 Treatment method |
| 05/02/2002 | US20020052387 5-Substituted 2-aryl-4-pyrimidinones |
| 05/02/2002 | US20020052386 Pyrimidine derivatives |
| 05/02/2002 | US20020052385 Administering 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline to a patient suffering from or at risk of developing ALS in order to reduce symptoms or delay onset of ALS. |
| 05/02/2002 | US20020052383 Phenylcycloalkylmethylamino and phenylalkenylamino derivatives, including 1-phenyl-2-aminomethylcyclopropanes; treatment of a variety of metabolic, feeding, and sexual disorders including obesity. |
| 05/02/2002 | US20020052382 R-hydroxynefazodone |
| 05/02/2002 | US20020052381 Method of using diketopiperazines and composition containing them |
| 05/02/2002 | US20020052379 Highly homogeneous form; stable pharmaceutical dosage forms, including an aqueous suspension |
| 05/02/2002 | US20020052378 Novel compounds and compositions as protease inhibitors |
| 05/02/2002 | US20020052377 Method for treating angina |
| 05/02/2002 | US20020052376 Imidazole derivatives and their use as farnesyl protein transferase inhibitors |
| 05/02/2002 | US20020052374 Pharmaceutical preparation containing at least folic acid or a folate and tetrahydrobiopterin (bh4) or derivatives thereof used for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase (nos) |